Notice Of Intent To Sole Source

This sole‑source contract awards the Baruch S. Blumberg Institute $75,000 to synthesize, scale‑up, and perform PK/ADME evaluations of A3 compound derivatives for the Medical University of South Carolina’s cancer research programs. The university cites the vendor’s exclusive prior work on the first‑in‑class inhibitor as the basis for the sole‑source justification, emphasizing that no comparable product exists and a change of supplier would jeopardize ongoing studies. The procurement manager, Leigh Gileno, is the point of contact for any inquiries, and interested parties must notify the university by July 29, 2026 if they wish to challenge the award. • Scope: chemical synthesis, scale‑up, and pharmacokinetic/ADME testing of proprietary compounds. • Value: $75,000 fixed‑price award. • Sole‑source rationale: unique expertise and prior synthesis of all compound derivatives, with no alternative suppliers.